Dynorphin is a recently discovered peptide belonging to the family of endogenous opioids (1). The first five amino acids at the NH2 terminus of dynorphin are identical to leucine-enkephalin; however, from position 6 to 13 it has a unique structure (the remainder ofthe peptide is currently unknown). While the anatomical localization of 3-endorphin and the enkephalins have been well described (2-19), little is currently known about the distribution of dynorphin. This peptide was extracted from porcine pituitaries and was purified by means ofa bioassay using the guinea pig ileum. We therefore elected to begin our studies on dynorphin immunocytochemistry by looking at rat pituitary and brain and at guinea pig ileum. We also extended our studies to guinea pig adrenal because of the previous reports of an enkephalin-like immunoreactivity in that organ.
separately from leucine-enkephalin. In other parts of brain and in the periphery the relationship between dynorphin and the enkephalins is very complex and requires further study and improved antisera.
Dynorphin is a recently discovered peptide belonging to the family of endogenous opioids (1) . The first five amino acids at the NH2 terminus of dynorphin are identical to leucine-enkephalin; however, from position 6 to 13 it has a unique structure (the remainder ofthe peptide is currently unknown). While the anatomical localization of 3-endorphin and the enkephalins have been well described (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , little is currently known about the distribution of dynorphin. This peptide was extracted from porcine pituitaries and was purified by means ofa bioassay using the guinea pig ileum. We therefore elected to begin our studies on dynorphin immunocytochemistry by looking at rat pituitary and brain and at guinea pig ileum. We also extended our studies to guinea pig adrenal because of the previous reports of an enkephalin-like immunoreactivity in that organ.
MATERIALS AND METHODS
Tissue preparation for immunocytochemistry was as described (17) . Antisera against dynorphin-(1-13) were prepared, with the resulting antigenic specificity largely directed toward a COOHterminal region (20) . Several antisera were produced, with similar specificities; that of highest titer (Lucia) was chosen, because it has been the most thoroughly characterized for radioimmunoassay (RIA). As published elsewhere (20) , the Lucia antiserum is used in RIA at titers of from 1:50,000 to 1:200,000
and crossreacts with leucine-enkephalin less than 10-8, and [3H]leucine-enkephalin does not appear to bind even in dilutions as low as 1:30. For peroxidase-antiperoxidase immunocytochemistry this antiserum was used at a 1:600 dilution for a 24-hr incubation at 40C (peroxidase-antiperoxidase and related reagents were from Sternberger-Meyer Immunocytochemical, Jarrettsville, MD).
.An important issue in the immunocytochemical study of dynorphin distribution in brain is the potential confusion with leucine-enkephalin-containing structures. The antiserum used in this study (Lucia) was raised against dynorphin-(1-13) (Peninsula Labs, San Carlos, CA) and its antigenic determinant includes residues 4 and 5 of dynorphin and leucine-enkephalin. While there is little crossreactivity with leucine-enkephalin under RIA conditions, the Lucia antiserum was used in a much more concentrated form for immunocytochemistry. It is therefore possible that the lower-affinity populations ofantibody may come into play under our immunocytochemical conditions, and that the crossreactivity with other peptides, including leucineenkephalin, may be different from that observed in RIA. For that reason complete control blocking studies were carried out on all tissues, using 2-20 A.M concentrations ofmethionine-and leucine-enkephalin, 8-endorphin, oxytocin, vasopressin, and dynorphin- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) .
In experiments in which relative concentrations ofdynorphin and enkephalin were determined, a combined high-performance liquid chromatography (HPLC)-RIA procedure was employed. All tissue was obtained fresh after decapitation, kept chilled on ice during dissection, then frozen immediately on dry ice and kept at -700C until extraction. Peptides were extracted with acetone/0.2 M HC1 (3:1, vol/vol) in the presence of peptidase inhibitors (0.01% phenylmethylsulfonyl fluoride and 0.01% iodoacetamide). Addition oflabeled materials showed recovery ofall opioid peptides, including dynorphin-(1-13), to exceed 90%. The extracts were concentrated in a Savant Speed Vac evaporator and applied to a reverse-phase column (octadecylsilica Ultrasphere; Altex, Berkeley, CA), using a pH 2.7 40 mM potassium phosphate buffer/acetonitrile gradient for peptide separation. Fractions from HPLC were collected, evaporated, and subjected to radioimmunoassay. Enkephalin RIA was carried out as described (21) . The leucine-enkephalin antiserum employed showed less than 2% crossreactivity with dynorphin-(1-13) or with methionine-enkephalin. Dynorphin RIA (using antiserum Lucia) was performed according to Ghazarossian et aL (20) . RESULTS
Immunocytochemistry ofrat brain revealed one heavily stained cell group (supraoptic nucleus; see The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. pressin/neurophysin systems in the hypothalamus. All of these demonstrations could be blocked by dynorphin-(1-13) at 2 ,uM (Fig. 1B) but not by any ofthe other peptides mentioned above at concentrations of20 , M. Ofparticular interest was the observation that very few fibers could be seen under these staining and fixation conditions. While it is usually the case that the magnocellular neuronal systems have abundant fiber systems throughout the hypothalamus, in the case of dynorphin no fibers could be detected. A more careful observation ofthe staining pattern in perikarya ofthe supraoptic nucleus suggested that the dynorphin staining in those cells was in the perinuclear area (Fig. IC) .
This pattern suggested a staining of nascent dynorphin. * Taken together with the absence of fiber staining in brain and the inability to trace dynorphin fibers from supraoptic nucleus to median eminence and posterior pituitary, this may indicate that dynorphin precursor was being stained preferentially over the completely processed peptides. Only where the fiber concentration of the final product is very high-as would be expected in the neurosecretory endings of the posterior pituitary-would we expect adequate visualization of the processed dynorphin.
Rat posterior pituitary was heavily stained by dynorphin antiserum while intermediate lobe and anterior lobe were left unstained ( Fig. 2A) . Dynorphin-(1-13) (2 uM) was capable of 4 blocking the posterior pituitary demonstration (Fig. 2B) . HowA~e ver, in contrast to the result with supraoptic nucleus, leucineenkephalin at very high concentration (20 AM) could produce a decrease of dynorphin staining of posterior pituitary; however, it could not eliminate it entirely. Because of recent work demonstrating the presence of leucine-enkephalin-like immunoreactivity in posterior pituitary (22) and the partial blockade of dynorphin staining by extremely large amounts of leucine-enkephalin, we carried out a biochemical characterization of the dynorphin and enkephalin immunoreactivity (21) in posterior pituitary. The results are presented in Fig. 3 . Virtually all the dynorphin immunoreactivity is contained in material that is more polar than leucine-enkephalin. None of the minor peaks coincide with authentic leucine-enkephalin. On the otherhand, leucine-enkephalin RIA (not shown) does detect material that cochromatographs with authentic leucine-enkephalin. Thus, it is possible to conclude that both peptides exist in posterior pit tuitary, a result consonant with that of Goldstein and Ghazarossian (23) . The relatively equal concentrations of leucine-enkephalin and dynorphin immunoreactivities suggest that our dynorphin demonstration is not due to crossreactivity with leucine-enkephalin, because a large excess of leucine-enkephalin _ A t was required to block the demonstration. Immunocytochemical studies on guinea pig adrenal (Fig. 4A ) were carried out because of the previous report of enkephalin immunoreactivity in the chromaffin cells of that gland (24) . In preliminary staining studies using dynorphin antiserum it was possible to demonstrate the adrenal medullary cells in guinea pig adrenal. These are the same cells that have been reported to produce leucine-enkephalin and the monoamines (24) . Control blocking studies, however, were quite different from what had been found in brain and pituitary, in that modest amounts (2 AM) of methionine-and leucine-enkephalin were capable of blocking cellular staining. We assayed dynorphin and leucineenkephalin content by RIA in a crude synapotosomal (P2) preparation of bovine adrenal prepared according to Holz (25) , then extracted as described above. There was approximately 425 times more leucine-enkephalin immunoreactivity than dynorphin immunoreactivity in this preparation (leucine-enkephalin immunoreactivity: 8.5 pmol/mg of P2; dynorphin immunoreactivity: 20 fmol/mg of P2). These results seem to suggest that the staining seen with Lucia antibody could have been from enkephalin crossreactivity.
Immunocytochemical staining of guinea pig ileum showed a heavy concentration of dynorphin-positive fibers in the submucous plexus (Fig. 4B) . Some of the fibers from the submucous plexus penetrated the circularis muscle toward the myenteric plexus located between the two muscle layers. This demonstration could be blocked by dynorphin-(1-13) and also by moderate amounts (10 uM) of methionine-and leucine-enkephalin. No biochemical studies have as yet been carried out on guinea pig ileum and therefore it is not possible yet to differentiate dynorphin from enkephalin staining in this organ.
DISCUSSION
We have demonstrated dynorphin-positive cell groups in hypothalamus, with probable projection to posterior pituitary. In the pars nervosa, it is clear from the present and previous work (23) that dynorphin and leucine-enkephalin exist in approximately equal amounts. This hypothalamic-pituitary dynorphinpositive system may be related to other magnocellular peptides, and appears to be separable from the enkephalin and the -endorphin systems. Thus stage but suggest a need for very careful biochemical evaluations in parallel with the immunocytochemistry until such time as immunocytochemically useful antibodies with even greater specificity for dynorphin are available.
